Research programme: anti-FLT3 radioimmunoconjugates - Eli Lilly and Company
Alternative Names: 177Lu-EB10; Flt-3 MAbLatest Information Update: 04 Nov 2017
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral, Injection)
- 28 Apr 2006 Preclinical trials in Haematological malignancies in USA (Parenteral)